Pharming raises €7.5 million in convertible debt

Tuesday 5 January 2010

Pharming Group NV has raised €7.5 million in convertible debt that will help finance its activities while its lead product for hereditary angioedema, Rhucin, is being reviewed by the European Medicines Agency.

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Location

Netherlands